Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

A Phase 2b Randomized Trial of Autologous Dendritic Cell Immunotherapy (CMN-001) Plus Standard Treatment of Advanced Renal Cell Carcinoma

CMN-001 is an autologous, tumor antigen-loaded dendritic cell immunotherapy. The active components of CMN-001 are autologous, matured dendritic cells, which have been co-electroporated with both in vitro transcribed (IVT) RNA from an autologous tumor specimen and CD40L RNA. CMN-001 is indicated for treatment of intermediate/poor risk patients with advanced renal cell carcinoma (RCC) in combination with nivolumab plus ipilimumab as first line therapy and in combination with lenvatinib plus everolimus as 2nd line therapy post 1st line failure.

Study Overview

• Status: Terminated
• Conditions: Advanced Renal Cell Carcinoma
• Intervention / Treatment: Biological: CMN-001; Biological: Nivolumab+Ipilimumab; Drug: Lenvatinib+Everolimus

• Study Type: Interventional
• Enrollment (Actual): 16
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • Florida
    • Tampa, Florida, United States, 33612
      • Moffitt Cancer Center
  • Georgia
    • Atlanta, Georgia, United States, 30322
      • Emory University
  • Minnesota
    • Rochester, Minnesota, United States, 55905
      • Mayo Clinic
  • New York
    • Syracuse, New York, United States, 13210
      • SUNY Upstate Medical University
    • Valhalla, New York, United States, 10595
      • Westchester Medical Center
  • Pennsylvania
    • Pittsburgh, Pennsylvania, United States, 15232
      • UPMC Hillman Cancer Center
  • Texas
    • Houston, Texas, United States, 77030
      • MD Anderson Cancer Center
    • Houston, Texas, United States, 77030
      • Houston Methodist
  • West Virginia
    • Morgantown, West Virginia, United States, 26506
      • West Virginia University Cancer Institute

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Age ≥ 18 years
2. Advanced disease histologically assessed as RCC, with predominantly clear cell histology
3. Metastatic disease (measurable or non-measurable) that can be monitored throughout the course of study participation per iRECIST
4. Subjects who are candidates for standard first-line therapy
5. Time from initial RCC diagnosis to initiation of systemic treatment (Nivolumab+Ipilimumab) of <1 year
6. Karnofsky Performance Status (KPS) ≥ 70%
7. Resolution of all acute toxic effects of prior radiotherapy or surgical procedures to Grade ≤ 1 according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0

8. Adequate hematologic function, as defined by central laboratory values for all three of the following criteria:

   1. Absolute neutrophil count (ANC) LLN, and
   2. Platelets 75,000/mm3 or 75.0 x 109/L, and
   3. Hemoglobin (Hgb) 8.0 g/dL

9. Adequate renal function, as defined by either of the following criteria:

   1. Serum creatinine 1.5 x upper limit of normal (ULN),
   2. OR, if serum creatinine greater than 1.5 x ULN, estimated glomerular filtration rate (eGFR) 30 mL/min

10. Adequate hepatic function, as defined by both of the following:

    1. Total serum bilirubin 1.5 x ULN
    2. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 2.5 x ULN or, AST and ALT 5 x ULN if liver function abnormalities are due to underlying malignancy

11. Adequate coagulation function as defined by either of the following criteria:

    1. INR < 1.5 x ULN
    2. For subjects receiving warfarin or LMWH, the subjects must, in the investigator's opinion, be clinically stable with no evidence of active bleeding while receiving anticoagulant therapy. The INR for these patients may exceed 1.5 x ULN if that is the goal of anticoagulant therapy.
12. Negative serum pregnancy test for female subjects with reproductive potential, and agreement of all male and female subjects of reproductive potential to use a reliable form of contraception during the study and for 12 weeks after the last dose of study drug
13. Normal ECG or clinically non-significant finding(s) at Screening, in the Investigator's opinion
14. Able to abstain from taking prohibited drugs, either prescription or non-prescription, during the treatment phase of the study
15. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
16. Signed and dated informed consent document indicating that the subject (or legally acceptable representative) has been informed of all pertinent aspects of the trial prior to enrollment

Exclusion Criteria:

1. Prior history of malignancy within the preceding 3 years, except for adequately treated in situ carcinomas or non-melanoma skin cancer, adequately treated early stage breast cancer, superficial bladder cancer, and non-metastatic prostate cancer with a normal PSA.
2. History of or known brain metastases, spinal cord compression, or carcinomatous meningitis, or evidence of brain or leptomeningeal disease

3. Patients will be excluded if they have <2 of the following risk factors at Screening:

   1. Time from diagnosis to systemic treatment < 1 year
   2. Hgb < LLN
   3. Corrected calcium > 10.0 mg/dL
   4. KPS < 80%
   5. Neutrophils > ULN
   6. Platelets > ULN
4. NCI CTCAE Grade 3 hemorrhage < 28 days before Visit 1 (Week 0)

5. Clinically significant cardiovascular conditions within 3 months prior to Randomization, which in the Investigator's opinion prohibits the initiation of standard targeted therapy, initiating with sunitinib, including:

   1. Cardiac angioplasty
   2. Myocardial infarction
   3. Unstable angina
   4. Coronary artery by-pass graft or stenting
   5. Class III or IV congestive heart failure (CHF), per NYHA Classification NOTE: Patients with left ventricular ejection fraction (LVEF) < LLN as assessed by either echocardiography or multiple gated acquisition (MUGA) scan, who are asymptomatic and are NOT classified as having NYHA Class III or IV CHF, may be eligible but should be monitored for LVEF changes while on sunitinib therapy as recommended in the current sunitinib prescribing information.
   6. Symptomatic peripheral vascular disease
   7. Cerebrovascular accident (CVA) or transient ischemic attack (TIA)
   8. Symptomatic or uncontrolled pulmonary embolism or deep vein thrombosis (DVT)
   9. Uncontrolled cardiac dysrhythmias of NCI CTCAE Grade ≥ 2, or prolongation of the QTc for males > 450 msec and for females > 470 msec as corrected by either the Fridericia or Bazett formula
   10. Uncontrolled or untreated atrial fibrillation
   11. Poorly controlled hypertension, defined as a systolic blood pressure (SBP), ≥ 150 mm Hg or diastolic blood pressure (DBP) ≥ 90 mm Hg NOTE: Initiation of antihypertensive medication(s) is permitted prior to study entry. Blood pressure must be re-assessed on 2 occasions separated by at least 1 hour. Mean SBP/DBP values must be less than 150/90 for eligibility.
   12. Evidence of active bleeding or a bleeding diathesis at Screening

6. Significant gastrointestinal abnormalities:

   1. Any history of major resection of the stomach or small bowel with ongoing impaired healing.
   2. Malabsorption syndrome with active symptoms in the Investigator's opinion, within 3 months prior to Randomization
   3. Active peptic ulcer, which cannot be appropriately managed in the Investigator's opinion, within 3 months prior to Randomization
   4. Intra-luminal bleeding lesions within 3 months prior to Randomization
   5. History of abdominal fistula or intra-abdominal abscess within 3 months prior to Randomization
7. Pre-existing thyroid abnormality with thyroid function that cannot be appropriately managed with medication, in the Investigator's opinion.

8. Active autoimmune disease or condition requiring chronic immunosuppressive therapy, such as rheumatoid arthritis, systemic lupus erythematous, multiple sclerosis, organ transplant recipient, etc.

   NOTE: Abnormal laboratory values for autoimmunity markers in the absence of other signs/symptoms of autoimmune disease are not exclusionary.

9. Clinically significant infections, including human immunodeficiency virus (HIV), syphilis, and active hepatitis B or C
10. Current treatment with an investigational therapy on another clinical trial
11. Pregnancy or breastfeeding
12. Any serious medical condition or illness considered by the investigator to constitute an unwarranted high risk for investigational treatment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Combination Arm; CMN-001 dosing (1x10^7 DC/dose) is initiated at Visit 2 during 1st line therapy and through 2nd line therapy. CMN-001 is administered as 1 dose every 3 weeks for 3 doses (Induction phase), followed by maintenance doses, 1 every 4 weeks for 7 doses (Maintenance phase), followed by booster doses, 1 dose every 12 weeks (Booster phase). 1st line therapy, Nivolumab (3mg/kg) + Ipilimumab (1 mg/kg) will be administered at 3 week intervals for 4 administrations starting at visit 1. Followed by Nivolumab (3 mg/kg) administration every 4 weeks until progression. After progression, 2nd line therapy with lenvatinib (18mg/day) + everolimus (5mg/day) until discontinuation criteria are met.	Biological: CMN-001; Autologous Dendritic Cell Therapy; Biological: Nivolumab+Ipilimumab; anti-PD-1 and anti-CTLA4 antibodies; Drug: Lenvatinib+Everolimus; TKI+mTOR inhibitors
Active Comparator: Standard Treatment; 1st line therapy, Nivolumab (3mg/kg) + Ipilimumab (1 mg/kg) will be administered at 3 week intervals for 4 administrations starting at visit 1. Followed by Nivolumab (3 mg/kg) administration every 4 weeks until progression. After progression 2nd line therapy with lenvatinib (18mg/day) + everolimus (5mg/day) until discontinuation criteria are met.	Biological: Nivolumab+Ipilimumab; anti-PD-1 and anti-CTLA4 antibodies; Drug: Lenvatinib+Everolimus; TKI+mTOR inhibitors

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall Survival	Patients will be followed for OS until the completion of the study.	Through study completion, an average of 2 years

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Monitor treatment emergent adverse events between both arms	Compare adverse events between both arms	Through study completion, an average of 2 years
Progression free survival	Progression-free survival from the date of subject randomization as assessed by the investigator per iRECIST. Radiological evidence of progression will be derived from tumor imaging assessments at baseline (Screening, Week 0) and restaging scans at Week 13, 21, 29, 37 then every 12 weeks until progression or study withdrawal.	Through study completion, an average of 2 years
Tumor Response	To compare tumor responses based on iRECIST between study arms	Through study completion, an average of 2 years

Collaborators and Investigators

• Sponsor: CoImmune

Study record dates

Study Major Dates

• Study Start (Actual): July 22, 2020
• Primary Completion (Actual): September 28, 2023
• Study Completion (Actual): September 28, 2023

Study Registration Dates

• First Submitted: December 10, 2019
• First Submitted That Met QC Criteria: December 17, 2019
• First Posted (Actual): December 18, 2019

Study Record Updates

• Last Update Posted (Actual): October 2, 2023
• Last Update Submitted That Met QC Criteria: September 28, 2023
• Last Verified: September 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Kidney Diseases; Urologic Diseases; Adenocarcinoma; Neoplasms, Glandular and Epithelial; Kidney Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Carcinoma, Renal Cell; Carcinoma; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Antineoplastic Agents; Immunosuppressive Agents; Immunologic Factors; Antineoplastic Agents, Immunological; Protein Kinase Inhibitors; Immune Checkpoint Inhibitors; MTOR Inhibitors; Nivolumab; Everolimus; Lenvatinib; Ipilimumab
• Other Study ID Numbers: CMN-001-1

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No